Patents Examined by Gian Wang
  • Patent number: 5320947
    Abstract: Methods for the detection, monitoring and treatment of malignancies are disclosed. Detection of the proliferation of T cells in response to in vitro exposure to a protein expression product of an activated oncogene or cancer-related gene associated with a malignancy, or detection of immunocomplexes formed between the protein expression product and antibodies in body fluid, allows the diagnosis of the presence of a malignancy. The present invention also discloses methods and compositions for treating a malignancy.
    Type: Grant
    Filed: January 13, 1992
    Date of Patent: June 14, 1994
    Assignee: Washington Research Foundation
    Inventors: Martin A. Cheever, David J. Peace
  • Patent number: 5198538
    Abstract: The disclosure describes novel immunosuppressive agents isolated from syncytiotrophoblast microvilli membranes by preparing a minutely subdivided and solubilized preparation of said membranes and isolating the unreduced N-linked oligosaccharides from an extract of said preparation.
    Type: Grant
    Filed: December 9, 1991
    Date of Patent: March 30, 1993
    Assignee: Monsanto Company
    Inventors: Peter D. Arkwright, Raymond A. Dwek, Christopher W. G. Redman, Graham A. W. Rook, Thomas W. Rademacher
  • Patent number: 5156957
    Abstract: Biologically active heterodimeric human FSH composed of an alpha subunit and a beta subunit, each subunit being synthesized by a cell having an expression vector containing heterologous DNA encoding the subunit.
    Type: Grant
    Filed: April 24, 1989
    Date of Patent: October 20, 1992
    Assignee: Genzyme Corporation
    Inventors: Vemuri B. Reddy, Nancy Hsiung, Anton K. Beck, Edward G. Berstine
  • Patent number: 5128255
    Abstract: The invention provides methods and products equal in a selection system for determining the presence or absence of a vector in a mammlian cell. The vector of the invention carries and is capable of expressing a gene encoding a protein capable of effecting the conversion of a precursor to an essential amino acid. A mammalian cell line is created with conditions capable of causing the vector to be introduced into the mammalian cell line. Then, the created mammalian cell line is grown in medium containing a precursors to the essential amino acid but not containing the growth-supporting amount of the essential amino acid and those cells capable of growing are selected.
    Type: Grant
    Filed: December 6, 1988
    Date of Patent: July 7, 1992
    Assignee: Gentest Corporation
    Inventor: Charles L. Crespi
  • Patent number: 5096822
    Abstract: The present invention is directed to a bovine embryo culture medium. The medium includes a culture solution containing the nutritional substances necessary to support a bovine embryo. One of the nutritional substances is hemicalcium lactate in an amount effective to maintain the health and viability of the bovine embryo. The culture medium is a preferred nuclear transfer medium.
    Type: Grant
    Filed: July 26, 1990
    Date of Patent: March 17, 1992
    Assignees: W. R. Grace & Co.- Conn., Charles F. Rosenkrans, Jr., Michelle M. Sims
    Inventors: Charles F. Rosenkrans, Jr., Carol L. Keefer, Michelle M. Sims
  • Patent number: 5091309
    Abstract: The present invention relates to RNA vectors comprising Sindbis virus DI RNA having inserted therein heterologous RNA. The vectors of the present invention provide for the cloning and expression of heterologous RNA in eucaryotic cells as well as the packaging of heterologous RNA into viral particles in the presence of helper virus. Transformed cells and genetically altered alphavirus particles comprising alphavirus DI RNA having inserted therein heterologous RNA are also provided.
    Type: Grant
    Filed: August 17, 1989
    Date of Patent: February 25, 1992
    Assignee: Washington University
    Inventors: Sondra Schlesinger, Henry V. Huang, Robin Levis, Barbara Weiss, Manuel Tsiang
  • Patent number: 5063157
    Abstract: The present invention provides a serum-free culture medium for mammalian cells, especially non-adherent cells, containing a base medium, transferrin, insulin and selenite, wherein it contains or consists of2 to 10 mg./liter transferrin,2 to 10 mg./liter insulin,1 to 10 g./liter peptone,10 to 500 mg./liter beta-D-xylopyranose substituted with phosphate, carboxyl and/or sulphate groups,0.1 to 0.5 mg./liter selenite and0.1 to 2 mg./liter biological polyamine.
    Type: Grant
    Filed: January 11, 1989
    Date of Patent: November 5, 1991
    Assignee: Boehringer Mannheim GmbH
    Inventor: Hubertus Stockinger
  • Patent number: 5061620
    Abstract: Human hematopoietic stem cells are provided by separation of the stem cells from dedicated cells. The stem cells may than be maintained by regeneration in an appropriate growth medium. Means are provided for assaying for the stem cells as to their capability for producing members of each of the hematopoietic lineages.
    Type: Grant
    Filed: March 30, 1990
    Date of Patent: October 29, 1991
    Assignee: SyStemix, Inc.
    Inventors: Ann Tsukamoto, Charles M. Baum, Yukoh Aihara, Irving Weissman